Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma

Marketwired
Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
Threshold Pharmaceuticals Logo
View Comments (0)